Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 401

1.

Prevalence of and Risk Factors for Total Hip and Knee Replacement in Retired National Football League Athletes.

Davies MAM, Kerr ZY, DeFreese JD, Arden NK, Marshall SW, Guskiewicz KM, Padua DA, Pietrosimone B.

Am J Sports Med. 2019 Oct;47(12):2863-2870. doi: 10.1177/0363546519870804. Epub 2019 Sep 9.

PMID:
31498654
2.

Increased Risk of Musculoskeletal Disorders and Mental Health Problems in Retired Professional Jockeys: A Cross-Sectional Study.

Mackinnon AL, Jackson K, Kuznik K, Turner A, Hill J, Davies MAM, Jones ME, Delmestri A, Sanchez-Santos MT, Newton J.

Int J Sports Med. 2019 Sep 3. doi: 10.1055/a-1004-5495. [Epub ahead of print] No abstract available.

3.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

4.

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.

Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0836. [Epub ahead of print]

PMID:
31439581
5.

Using longitudinal targeted maximum likelihood estimation in complex settings with dynamic interventions.

Schomaker M, Luque-Fernandez MA, Leroy V, Davies MA.

Stat Med. 2019 Aug 22. doi: 10.1002/sim.8340. [Epub ahead of print]

PMID:
31436859
6.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
7.

Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.

Schvartsman G, Ma J, Bassett RL Jr, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC.

Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454. [Epub ahead of print]

PMID:
31398264
8.

Increased Risk of Musculoskeletal Disorders and Mental Health Problems in Retired Professional Jockeys: A Cross-Sectional Study.

Mackinnon AL, Jackson K, Kuznik K, Turner A, Hill J, Davies MAM, Jones ME, Delmestri A, Sanchez-Santos MT, Newton J.

Int J Sports Med. 2019 Oct;40(11):732-738. doi: 10.1055/a-0902-8601. Epub 2019 Aug 7.

9.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0340-7. [Epub ahead of print]

PMID:
31383963
10.

Cleansing-induced changes in skin measured by in vivo confocal raman spectroscopy.

Davies MA.

Skin Res Technol. 2019 Aug 1. doi: 10.1111/srt.12760. [Epub ahead of print]

PMID:
31373073
11.

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.

Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-1259. [Epub ahead of print]

PMID:
31371342
12.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

13.

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE.

Mol Cancer Ther. 2019 Sep;18(9):1637-1648. doi: 10.1158/1535-7163.MCT-18-1056. Epub 2019 Jul 3.

PMID:
31270153
14.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
15.

Changes in rapid HIV treatment initiation after national "treat all" policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis.

Tymejczyk O, Brazier E, Yiannoutsos CT, Vinikoor M, van Lettow M, Nalugoda F, Urassa M, Sinayobye JD, Rebeiro PF, Wools-Kaloustian K, Davies MA, Zaniewski E, Anderegg N, Liu G, Ford N, Nash D; IeDEA consortium.

PLoS Med. 2019 Jun 10;16(6):e1002822. doi: 10.1371/journal.pmed.1002822. eCollection 2019 Jun.

16.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
17.

AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL.

Mol Cancer Res. 2019 Sep;17(9):1787-1800. doi: 10.1158/1541-7786.MCR-18-1372. Epub 2019 May 28.

PMID:
31138602
18.

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

Brastianos P, Davies MA, Margolin K, Yu HA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e59-e69. doi: 10.1200/EDBK_241345. Epub 2019 May 17.

PMID:
31099629
19.

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A.

J Immunother Cancer. 2019 Apr 17;7(1):107. doi: 10.1186/s40425-018-0469-9.

20.

The prevalence of hand and wrist osteoarthritis in elite former cricket and rugby union players.

Jones ME, Davies MAM, Shah K, Kemp S, Peirce N, Leyland KM, Stokes KA, Judge AD, Newton JL, Furniss D, Arden NK.

J Sci Med Sport. 2019 Aug;22(8):871-875. doi: 10.1016/j.jsams.2019.03.004. Epub 2019 Mar 16.

21.

Timing of combination antiretroviral therapy (cART) initiation is not associated with stillbirth among HIV-infected pregnant women in Malawi.

Msukwa MT, Keiser O, Jahn A, van Oosterhout JJ, Edmonds A, Phiri N, Manjomo R, Davies MA, Estill J.

Trop Med Int Health. 2019 Jun;24(6):727-735. doi: 10.1111/tmi.13233. Epub 2019 Apr 1.

PMID:
30891866
22.

What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.

Patten G, Schomaker M, Davies MA, Rabie H, van Zyl G, Technau K, Eley B, Boulle A, Van Dyke RB, Patel K, Sipambo N, Wood R, Tanser F, Giddy J, Cotton M, Nuttall J, Essack G, Karalius B, Seage G, Sawry S, Egger M, Fairlie L; for IeDEA Southern Africa.

Pediatr Infect Dis J. 2019 Apr;38(4):400-405. doi: 10.1097/INF.0000000000002156.

PMID:
30882732
23.

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC.

J Neurooncol. 2019 May;142(3):499-509. doi: 10.1007/s11060-019-03121-2. Epub 2019 Mar 7.

PMID:
30847840
24.

How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?

Euvrard J, Schulz T, Hilderbrand K, Bosland M, Osler M, Boulle A, Davies MA.

S Afr Med J. 2019 Feb 26;109(3):174-177. doi: 10.7196/SAMJ.2019.v109i3.13456.

25.

Reply to A. Shinde et al.

Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL.

J Clin Oncol. 2019 Apr 20;37(12):1031-1032. doi: 10.1200/JCO.18.02463. Epub 2019 Feb 26. No abstract available.

PMID:
30807233
26.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

PMID:
30787016
27.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
28.

Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA).

Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, Parcesepe AM, Onovo A, Lancaster KE, Castelnuovo B, Murnane PM, Cohen CR, Vreeman RC, Davies MA, Duda SN, Yiannoutsos CT, Bono RS, Agler R, Bernard C, Syvertsen JL, Sinayobye JD, Wikramanayake R, Sohn AH, von Groote PM, Wandeler G, Leroy V, Williams CF, Wools-Kaloustian K, Nash D; IeDEA Treat All in sub-Saharan Africa Consensus Statement Working Group.

J Int AIDS Soc. 2019 Jan;22(1):e25218. doi: 10.1002/jia2.25218. Review.

29.

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.

Panayidou K, Davies MA, Anderegg N, Egger M; IeDEA, COHERE, PHACS and IMPAACT 219C Collaborations Writing Group.

J Int AIDS Soc. 2018 Nov;21(11):e25200. doi: 10.1002/jia2.25200.

30.

Treatment outcomes in perinatally infected HIV-positive adolescents and young adults after ≥10 years on antiretroviral therapy.

Anderson K, Muloiwa R, Davies MA.

S Afr Med J. 2018 Dec 13;109(1):27-34. doi: 10.7196/SAMJ.2018.v109i1.13230.

31.

Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration.

Kariminia A, Law M, Davies MA, Vinikoor M, Wools-Kaloustian K, Leroy V, Edmonds A, McGowan C, Vreeman R, Fairlie L, Ayaya S, Yotebieng M, Takassi E, Pinto J, Adedimeji A, Malateste K, Machado DM, Penazzato M, Hazra R, Sohn AH; IeDEA.

J Int AIDS Soc. 2018 Dec;21(12):e25215. doi: 10.1002/jia2.25215.

32.

HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling.

de Waal R, Lessells R, Hauser A, Kouyos R, Davies MA, Egger M, Wandeler G.

J Virus Erad. 2018 Nov 15;4(Suppl 2):55-58.

33.

Traversing the cascade: urgent research priorities for implementing the 'treat all' strategy for children and adolescents living with HIV in sub-Saharan Africa.

Enane LA, Davies MA, Leroy V, Edmonds A, Apondi E, Adedimeji A, Vreeman RC.

J Virus Erad. 2018 Nov 15;4(Suppl 2):40-46.

34.

The contribution of observational studies in supporting the WHO 'treat all' recommendation for HIV/AIDS.

Ford N, Penazzato M, Vitoria M, Doherty M, Davies MA, Zaniewski E, Tymejczyk O, Egger M, Nash D.

J Virus Erad. 2018 Nov 15;4(Suppl 2):5-8.

35.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
36.

Neonatal and infant diagnostic HIV-PCR uptake and associations during three sequential policy periods in Cape Town, South Africa: a longitudinal analysis.

Kalk E, Kroon M, Boulle A, Osler M, Euvrard J, Stinson K, Timmerman V, Davies MA.

J Int AIDS Soc. 2018 Nov;21(11):e25212. doi: 10.1002/jia2.25212.

37.

Impact of "test and treat" recommendations on eligibility for antiretroviral treatment: Cross sectional population survey data from three high HIV prevalence countries.

Chihana ML, Huerga H, Van Cutsem G, Ellman T, Wanjala S, Masiku C, Szumilin E, Etard JF, Davies MA, Maman D.

PLoS One. 2018 Nov 26;13(11):e0207656. doi: 10.1371/journal.pone.0207656. eCollection 2018.

38.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
39.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
40.

Lamivudine monotherapy as a holding regimen for HIV-positive children.

Patten G, Bernheimer J, Fairlie L, Rabie H, Sawry S, Technau K, Eley B, Davies MA; for IeDEA Southern Africa.

PLoS One. 2018 Oct 11;13(10):e0205455. doi: 10.1371/journal.pone.0205455. eCollection 2018.

41.

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A.

J Immunother Cancer. 2018 Oct 11;6(1):103. doi: 10.1186/s40425-018-0412-0. Erratum in: J Immunother Cancer. 2019 Apr 17;7(1):107.

42.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

43.

Partial mid-portion Achilles tear resulting in substantial improvement in pain and function in an amateur long-distance runner.

Woyton MM, Kluzek S, Wedatilake T, Davies MAM.

BMJ Case Rep. 2018 Sep 19;2018. pii: bcr-2018-225823. doi: 10.1136/bcr-2018-225823.

PMID:
30232204
44.

Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency.

Boettiger DC, Law MG, Sohn AH, Davies MA, Wools-Kaloustian K, Leroy V, Yotebieng M, Vinikoor M, Vreeman R, Amorissani-Folquet M, Edmonds A, Fatti G, Batte J, Renner L, Adedimeji A, Kariminia A; International Epidemiology Databases to Evaluate AIDS.

J Pediatric Infect Dis Soc. 2018 Sep 11. doi: 10.1093/jpids/piy087. [Epub ahead of print]

PMID:
30215763
45.

Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts.

de Waal R, Cohen K, Boulle A, Fox MP, Maartens G, Igumbor EU, Davies MA.

PLoS One. 2018 Sep 5;13(9):e0203530. doi: 10.1371/journal.pone.0203530. eCollection 2018.

46.

Antibiotic use and resistance: Knowledge, attitudes and perceptions among primary care prescribers in South Africa.

Farley E, Stewart A, Davies MA, Govind M, Van den Bergh D, Boyles TH.

S Afr Med J. 2018 Aug 28;108(9):763-771. doi: 10.7196/SAMJ.2018.v108i9.12933.

47.

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE.

Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16.

48.

Sex as a predictor of response to cancer immunotherapy.

McQuade JL, Daniel CR, Hess KR, Davies MA.

Lancet Oncol. 2018 Aug;19(8):e376. doi: 10.1016/S1470-2045(18)30483-2. No abstract available.

PMID:
30102226
49.

Assessing the risk of dolutegravir for women of childbearing potential.

Schomaker M, Davies MA, Cornell M, Ford N.

Lancet Glob Health. 2018 Sep;6(9):e958-e959. doi: 10.1016/S2214-109X(18)30326-7. Epub 2018 Jul 23. No abstract available.

50.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

Supplemental Content

Loading ...
Support Center